Addition of navitoclax to the first-line, standard TB treatment (rifampin – R, isoniazid – H and pyrazinamide – Z, RHZ regimen) promotes pulmonary bacterial clearance and reduces lung damage in mouse models of TB, by inhibiting tissue Bcl-2 expression. Here, BCL2 is linked to tuberculosis.